CAT

872.73

-1.6%↓

323.21

+0.91%↑

GEV.US

969.02

-2.68%↓

RTX

179.04

-0.15%↓

230.8

+0.78%↑

CAT

872.73

-1.6%↓

323.21

+0.91%↑

GEV.US

969.02

-2.68%↓

RTX

179.04

-0.15%↓

230.8

+0.78%↑

CAT

872.73

-1.6%↓

323.21

+0.91%↑

GEV.US

969.02

-2.68%↓

RTX

179.04

-0.15%↓

230.8

+0.78%↑

CAT

872.73

-1.6%↓

323.21

+0.91%↑

GEV.US

969.02

-2.68%↓

RTX

179.04

-0.15%↓

230.8

+0.78%↑

CAT

872.73

-1.6%↓

323.21

+0.91%↑

GEV.US

969.02

-2.68%↓

RTX

179.04

-0.15%↓

230.8

+0.78%↑

Начало・Списък с акции・Ocugen Inc

Ocugen Inc

Затворен

1.37 -2.84

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

1.37

Максимум

1.38

Ключови измерители
By Trading Economics
Приходи	-1.5M -19M
Продажби	1.7M 1.5M
EPS	-0.06
Марж на печалбата	-1,250.946
Служители	116
EBITDA	-987K -17M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+728.26% upside

Дивиденти
By Dow Jones
Следващи печалби	31.07.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	-173M 454M
Предишно отваряне	4.21
Предишно затваряне	1.37

Ocugen Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

29.05.2026 г., 23:08 ч. UTC

Придобивния, сливания и поглъщания

Family Offices Bypass Private Equity and Go Direct -- Barrons.com

29.05.2026 г., 23:06 ч. UTC

Придобивния, сливания и поглъщания

After a Series of Sales, Hims Director Buys Company Shares -- Barrons.com

29.05.2026 г., 20:53 ч. UTC

Печалби

Oil Declines Lift Stocks to Fresh Records -- WSJ

29.05.2026 г., 20:50 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

29.05.2026 г., 20:33 ч. UTC

Пазарно говорене

Canada Meets Only One of Three Criteria To Declare Recession -- Market Talk

29.05.2026 г., 20:11 ч. UTC

Печалби

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29.05.2026 г., 19:47 ч. UTC

Печалби

These Were the Best and Worst S&P 500 Stocks in May -- Barrons.com

29.05.2026 г., 19:36 ч. UTC

Пазарно говорене

U.S. Natural Gas Futures End Month With Gains -- Market Talk

29.05.2026 г., 19:34 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

29.05.2026 г., 19:34 ч. UTC

Пазарно говорене

Over Half of Canadian Industries Growing, Undermining Recession Talk -- Market Talk

29.05.2026 г., 19:22 ч. UTC

Пазарно говорене

Oil Falls as U.S., Iran Expected to Reach Agreement -- Market Talk

29.05.2026 г., 19:05 ч. UTC

Придобивния, сливания и поглъщания

Universal Music Group Rejects $65 Billion Takeover Bid From Bill Ackman's Pershing Square -- Barrons.com

29.05.2026 г., 18:19 ч. UTC

Пазарно говорене

Canada Technical Recession Chatter Rife But Per-Capita GDP Was Up -- Market Talk

29.05.2026 г., 18:12 ч. UTC

Придобивния, сливания и поглъщания

Universal Music Group Rejects $65 Billion Buyout Offer From Bill Ackman -- WSJ

29.05.2026 г., 18:11 ч. UTC

Пазарно говорене

Canada Households Reaching Limit at Keeping Spending in Positive Territory -- Market Talk

29.05.2026 г., 18:10 ч. UTC

Пазарно говорене

As BTC Long-Term Holders Rise, Short-Term Holders Flee -- Market Talk

29.05.2026 г., 17:55 ч. UTC

Печалби

Okta Stock Soars. What's Stealing the Show From Earnings. -- Barrons.com

29.05.2026 г., 17:55 ч. UTC

Пазарно говорене

NEAR Protocol Nearly Doubles in May -- Market Talk

29.05.2026 г., 17:38 ч. UTC

Пазарно говорене

U.S. Oil Rig Count Rises for Fifth Straight Week -- Market Talk

29.05.2026 г., 17:00 ч. UTC

Печалби

Okta Stock Soars After Earnings. Results Aren't the Real Catalyst. -- Barrons.com

29.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Financial Services Roundup: Market Talk

29.05.2026 г., 16:20 ч. UTC

Пазарно говорене

Health Care Roundup: Market Talk

29.05.2026 г., 16:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

29.05.2026 г., 16:02 ч. UTC

Пазарно говорене

Gold Extend Gains as Investors Await U.S.-Iran Deal News -- Market Talk

29.05.2026 г., 15:55 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

29.05.2026 г., 15:55 ч. UTC

Пазарно говорене

Cryptocurrencies Appear Detached From Stocks -- Market Talk

29.05.2026 г., 15:50 ч. UTC

Придобивния, сливания и поглъщания

Johnson Matthey CEO: Cormetech Acquisition to Drive Growth

29.05.2026 г., 15:50 ч. UTC

Придобивния, сливания и поглъщания

Johnson Matthey CEO: Demand for AI Data Centers Insatiable

29.05.2026 г., 15:40 ч. UTC

Пазарно говорене

Kalshi To Launch Crypto Perpetual Futures -- Market Talk

29.05.2026 г., 15:20 ч. UTC

Пазарно говорене

Canada's Economy Not Looking All That Bright -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Ocugen Inc Прогноза

Ценова цел

By TipRanks

728.26% нагоре

12-месечна прогноза

Среден 11.43 USD 728.26%

Висок 22 USD

Нисък 7 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Ocugen Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на Ocugen Inc през последните 3 месеца.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.